These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016 [TBL] [Abstract][Full Text] [Related]
10. [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia]. Plander M; Skrapits J; Bozsó T; Szendrei T; Iványi JL Orv Hetil; 2012 Oct; 153(41):1622-8. PubMed ID: 23045312 [TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Dreger P; Ritgen M; Böttcher S; Schmitz N; Kneba M Leukemia; 2005 Jul; 19(7):1135-8. PubMed ID: 16074500 [No Abstract] [Full Text] [Related]
12. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples. Bento L; Correia R; de Sousa F; Vaz A; Pedro E; Schimidell D; Millan N; Passaro M; Barroso R; Bacal N Cytometry B Clin Cytom; 2020 Nov; 98(6):529-535. PubMed ID: 32251553 [TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. Tomuleasa C; Selicean C; Cismas S; Jurj A; Marian M; Dima D; Pasca S; Petrushev B; Moisoiu V; Micu WT; Vischer A; Arifeen K; Selicean S; Zdrenghea M; Bumbea H; Tanase A; Grewal R; Pop L; Aanei C; Berindan-Neagoe I Crit Rev Clin Lab Sci; 2018 Aug; 55(5):329-345. PubMed ID: 29801428 [TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease assessment in chronic lymphocytic leukaemia. Sayala HA; Rawstron AC; Hillmen P Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836 [TBL] [Abstract][Full Text] [Related]
15. The detection and significance of minimal residual disease in acute and chronic leukemia. Chung NG; Buxhofer-Ausch V; Radich JP Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250 [TBL] [Abstract][Full Text] [Related]
16. Eradication of minimal residual disease in chronic lymphocytic leukemia. Schweighofer CD; Hallek M; Wendtner CM Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447 [TBL] [Abstract][Full Text] [Related]
17. Detection of minimal residual disease in B-cell chronic lymphocytic leukaemia by flow cytometry. García Vela JA; Delgado I; García Alonso L; Monteserin MC; Benito L; Oña F; Lastra AM Br J Haematol; 1997 Nov; 99(2):464-5. PubMed ID: 9375774 [No Abstract] [Full Text] [Related]
18. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580 [TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in chronic lymphocytic leukaemia. García Vela JA; García Marco JA Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095 [TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Aw A; Kim HT; Fernandes SM; Hoang K; Kasar S; Faham M; Brown JR Leuk Lymphoma; 2018 Aug; 59(8):1986-1989. PubMed ID: 29164966 [No Abstract] [Full Text] [Related] [Next] [New Search]